Blood Disorder News and Research

RSS

UCSF researchers find way to knock down cancers caused by myc protein

UC San Francisco researchers have found a way to knock down cancers caused by a tumor-driving protein called "myc," paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.

19 Jul 2013

Breast cancer pilot study: Patients benefit from treatments guided by molecular profiling

The Side-Out Foundation's breast cancer pilot study, led by the Translational Genomics Research Institute, Translational Drug Development and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling.

18 Jul 2013

Administering immunoglobulins to pregnant women may prevent Rh blood disorder in newborns

Swedish researchers determined that administering anti-D antibodies (immunoglobulins) to pregnant women who were Rhesus D (RhD) negative could prevent hemolytic disease in the infant.

27 Jun 2013

VCU researchers shed light on biopsychosocial, spiritual effects of taking opioids for noncancer pain

Researchers from Virginia Commonwealth University sought to shed light on the biopsychosocial and spiritual effects of taking prescribed opioids to treat noncancer pain.

15 Apr 2013

Two studies shed light on molecular biology of three blood disorders

Two studies led by investigators at Weill Cornell Medical College shed light on the molecular biology of three blood disorders, leading to novel strategies to treat these diseases.

26 Mar 2013

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).

16 Feb 2013

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

23 Jan 2013

Penn Medicine to establish new center for treatment and research of blood diseases

Penn Medicine will establish the Philadelphia region's first dedicated center for the treatment and research of blood diseases by combining the expertise of physicians who specialize in the care of blood disorder patients of all ages along with basic science and clinical researchers who are working to advance treatments for these illnesses.

18 Jan 2013

Studies examine current treatment standards for patients with clotting disorders

Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes.

11 Dec 2012

Research unveils key gaps in continuity of care for sickle cell patients

Research unveiling key gaps in continuity of care for sickle cell patients transitioning from pediatric to adult care will be presented this week during the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Hereditary blood disorder found in South-East Asia, South-West Pacific could offer clues for malaria vaccine

"A team of international scientists has found that a type of hereditary disorder in some communities in South-East Asia and the South-West Pacific protects its sufferers from malaria, a finding that could drive future vaccine design," SciDev.Net reports.

19 Sep 2012

Emmaus Medical to complete target enrollment in L-Glutamine Phase III trial for sickle cell disease

In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.

14 Sep 2012

Researchers discover small DNA sequence that drives GATA2 protein

The protein GATA2 is known as a "master regulator" of blood cell development. When a mutation occurs in the gene that makes GATA2, serious blood diseases such as acute myeloid leukemia can result.

11 Sep 2012

Diabetes prevention: an interview with Julian Baines, CEO of EKF Diagnostics

NICE public health guideline 38 ‘Preventing type 2 diabetes: Risk identification and interventions for individuals at high risk’.

From EKF Diagnostics 3 Sep 2012

Targeted intervention improves safety of MRI scans for children with sickle cell disease

Jude Children's Research Hospital reports success using a targeted educational approach to teach young patients to remain motionless during MRI scans, making the process safer.

1 Sep 2012

Anemia prevention in pregnancy: an interview with Juan Pablo Peña-Rosas, WHO

Anaemia is a condition in which the number of red blood cells in the body is lower than normal or these have lower amounts of haemoglobin, a protein that is involved in the oxygen exchange of the body.

10 Aug 2012

Alexion second quarter net product sales increase to $274.7 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2012.

25 Jul 2012

HemoGlobe device can identify women with anemia

Could a low-cost screening device connected to a cell phone save thousands of women and children from anemia-related deaths and disabilities? That's the goal of Johns Hopkins biomedical engineering undergraduates who've developed a noninvasive way to identify women with this dangerous blood disorder in developing nations. The device, HemoGlobe, is designed to convert the existing cell phones of health workers into a "prick-free" system for detecting and reporting anemia at the community level.

25 Jul 2012

Emmaus receives EC Orphan Medicinal Product designation for Levoglutamide

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company's investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease.

18 Jul 2012

Eltrombopag can raise blood cell levels in some people with severe aplastic anemia

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies.

5 Jul 2012